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ABSTRACT
BOB.1/OBF.1 is a lymphocyte-restricted transcrip-
tional coactivator. It binds together with the Oct1
and Oct2 transcription factors to DNA and enhances
their transactivation potential. Mice deficient for the
transcriptional coactivator BOB.1/OBF.1 show sev-
eral defects in differentiation, function and signaling
of B cells. In search of BOB.1/OBF.1 regulated genes
we identified Btk—a cytoplasmic tyrosine kinase—as
adirecttargetofBOB.1/OBF.1.Analysesofthehuman
as well as murine Btk promoters revealed a non-
consensus octamer site close to the start site of tran-
scription. Here we show that Oct proteins together
with BOB.1/OBF.1are able toform ternary complexes
on these sites in vitro and in vivo. This in turn leads
to the induction of Btk promoter activity in synergism
with the transcription factor PU.1. Btk, like BOB.1/
OBF.1, plays a critical role in B cell development
and B cell receptor signalling. Therefore the down-
regulation of Btk expression in BOB.1/OBF.1-
deficient B cells could be related to the functional
and developmental defects observed in BOB.1/
OBF.1-deficient mice.
INTRODUCTION
The octamer motif ATGCAAAT is important for B cell-
speciﬁc gene regulation.Althoughit isalso foundinpromoters
of ubiquitously expressed genes (1–3), it is a critical element
in the regulatory regions of several B cell-speciﬁc expressed
genes, like immunoglobulin genes (4,5), B29 (Igb), CD20
and CD21 (6–8). Detailed analyses of the octamer sequence
revealed that mutations in most positions of the conserved
motif interfere with its function (9). In B cells, two octamer
transcription factors bind to the octamer element, the ubiquit-
ously expressed Oct1 and the lymphocyte-speciﬁc expressed
Oct2 (10). For B-cell-speciﬁc activity these transcription fac-
tors need to interact with an additional lymphocyte-restricted
coactivator named BOB.1/OBF.1 (alternative names are
Bob.1, OBF-1, OCA-B) (11,12). BOB.1/OBF.1 displays
only weak DNA binding and is recruited to the octamer
sequence predominantly via interaction of its N-terminal
domain with the POU-domains of Oct factors (11–19). The
transactivation domains of both type of proteins—Oct and
BOB.1/OBF.1—act in synergy to mediate octamer-dependent
transcription. A BOB.1/OBF.1 protein isoform bearing an
N-terminal myristoylated extension was found to be localized
in the membrane fraction (20). The function of this isoform
is not understood yet.
Gene targeting experiments revealed that BOB.1/OBF.1 is
important at several stages of B cell development in the bone
marrow as well as in peripheral secondary lymphoid tissues. In
the bone marrow the number of immature as well transitional
B cells is reduced and fewer cells reach the periphery (21).
BOB.1/OBF.1 is expressed throughout B cell ontogeny, albeit
at different levels. The highest expression is found in germinal
center B cells (22,23). The most striking characteristic of
BOB.1/OBF.1
 /  mice is the complete failure to form ger-
minal centers in spleen and lymph nodes (24–26). Therefore,
the production of switched immunoglobulin isotypes is
strongly reduced. In addition, the development of the marginal
zone B cell compartment in BOB.1/OBF.1
 /  mice is severely
affected (27). The B-cell-speciﬁc expression of a
bcl2-transgene can rescue several aspects of early lymph-
opoiesis in BOB.1/OBF.1
 /  mice. However, terminal differ-
entiation and speciﬁc B cell responses are still defective (28).
BOB.1/OBF.1 is also inducible expressed in T cells (29,30). A
critical function in T cells has however not been identiﬁed yet.
Some of the defects in early and late B cell development
as well as in B cell function were reminiscent of defects in
mice deﬁcient of functional Bruton’s tyrosine kinase (Btk).
Mutations in the gene coding for Btk cause X-linked
agammaglobulinemia (XLA) in humans (31) and X-linked
immunodeﬁciency (Xid) in mice [reviewed in Ref. (32)].
The Xid phenotype ischaracterized by a defect inthe transition
from the pre-B to immature B cells in the bone marrow as well
as by a reduced number of peripheral B cells that exhibit an
immature phenotype (33–35). In addition, the B-1 cell com-
partment is absent in Xid-mice. Consequently, the levels of
serum IgM and IgG3 are low. Similar to BOB.1/OBF.1
 / 
animals (25,27), mice deﬁcient for an functional Btk show
severe defects in B cell receptor signaling, expressed by
reduced tyrosine phosphorylation [reviewed in (32)], reduced
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2+ levels (36), reduced activation
of NF-kB (37,38) as well as impaired proliferation upon IgM
crosslinking (33,34). Based on these ﬁndings one may suggest
that BOB.1/OBF.1 and Btk have overlapping functions.
However, mice mutant for both proteins almost completely
lack peripheral B cells and show a severe agammaglobu-
linemia (39), a phenotype resembling human XLA (31).
Thus, although BOB.1/OBF.1 and Btk share some overlapping
functions, they are also involved in distinct signaling
pathways, which are important for B cell development and
function.
To get insights into the regulation of Btk expression the
human (40,41) and murine (42,43) promoter regions were
analyzed for conserved regulatory elements (44–49).
Recently, regulatory elements necessary for Btk gene activa-
tion were also identiﬁed in intron1. The btk promoter does
not contain an obvious TATA box. Transcription is initiated
at a putative initiator element. Deletion analyses revealed that
a sequence of 280 bp upstream of the start site of transcription
is sufﬁcient for the cell-type-speciﬁc regulation of Btk expres-
sion. The transcription factors Sp1, Sp3, Spi-B and PU.1
are able to synergistically activate the Btk promoter. However,
in PU.1-deﬁcient fetal liver cells (48) as well as SP1
 / 
embryonic stem cells (49), Btk expression was either reduced
or not affected but not abolished. This indicates that addi-
tional, yet not identiﬁed factors also contribute to Btk pro-
moter activity.
Here we show that the transcription factors Oct1 and Oct2
are able to bind in concert with the coactivator BOB.1/OBF.1
to a non-perfect octamer site within the human and murine Btk
promoters leading to their activation. Moreover, Oct and
BOB.1/OBF.1 proteins activate the murine Btk promoter syn-
ergistically with PU.1. The importance of the Oct/BOB.1/
OBF.1-mediated btk gene activation is underlined by the
fact that in BOB.1/OBF.1-deﬁcient B cells expression of
Btk is impaired. Thus, we identiﬁed the non-perfect octamer
site present in human as well in the murine Btk promoter as a
conserved regulatory site important for B cell-speciﬁc btk
gene regulation.
MATERIALS AND METHODS
Mice
C57BL/6 wild type and BOB.1/OBF.1
 /  mice on the same
genetic background as well as the 1.5/B.1
 /  mice were
obtained from our breeding facility. Mice were analyzed
8–12 weeks after birth. The generation of mice 1.5/B.1
 / ,
transgenic for mE-tTa and tetO-BOB.1/OBF.1 has been
described (21).
B220
+ cell sorting
Cells were labeled with an anti-B220-biotin-antibody and
revealed by Streptavidin-Cy-Chrom and subsequently sorted
with a FACSORT plus cytometer (Becton Dickinson).
Stainings were performed in PBS containing 0.1% BSA
(Roche Diagnostics, Mannheim, GER), 0.1% Na-azid and
saturating concentrations of anti-CD16/CD32 to block
FcgIII/II receptors. All antibodies were purchased from
Becton Dickinson.
B220
+ cell enrichment from mice spleens
Single cell suspensions from mouse splenocytes were incub-
ated with antibodies against CD4, CD8 (derived from an
antibody-producing hybridoma cell line) and positive cells
were eliminated by complement lysis using baby rabbit
complement (Cedarlane). This treatment was followed by a
lympholyte M gradient (Cedarlane) to eliminate red blood as
well as dead cells. The purity of the B220
+ B cell population
was >95%.
Cell culture, cell lines and transfections
NIH/3T3 and HeLa cells were cultured in DMEM (Life
Technologies, Inc.), BJAB and S194 cells in RPMI (Life
Technologies, Inc.) supplemented both with 10% FCS,
antibiotics and 50 mM b-ME, and grown at 37 C and 5%
CO2. Transfections of NIH/3T3 cells were performed by
electroporation (Bio-Rad) with 450 Vand 250 mFin phosphate
buffered saline.
Pre-B cell lines were established by culturing bone marrow
cells from mice of the indicated genotype under the stimulat-
ory inﬂuence of irradiated adherent stromal cells ST2 and the
cytokine IL-7. As culture medium was used IMDM (Life
Technologies, Inc.) supplemented with 5% FCS, antibiotics,
50 mM b-ME, 2% supernatant from IL-7 producing cells J558
(A. Rolink, Basel) and 5% Primatone (PAN Systems GmbH).
Cells were grown at 37 C and 10% CO2.
Plasmids
The murine Btk promotor ( 436 to +79) was cloned into
the pTKL/2 vector containing the HSV-thymidine kinase
promoter ( 105 to +52) from the pBLCAT2 in front of the
ﬁreﬂy luciferase coding region. The HSV-thymidine kinase
promoter was excised by a restriction endonuclease digest
using HindIII and BglII and replaced by the Btk promoter
cloned via genomic PCR using the following primers:
mBtkpr-HindIII: GAG TAA GCT TTC TTT GTC TGT
CCT CC; mBtkprom-BglII: TGA GAT GCC AGA TCT
TGG AAG GTG. The mutant Btk promoter was created by
site-directed in vitro mutagenesis (Stratagene) using the fol-
lowing primers: mBTKprom 3M 5’: GTA AAG AGG TCC
CAG TAC AAT GTC GGG GGG TGG; mBTKprom 3M 3’:
CCA CCC CCC GAC ATT GTA CTG GGA CCT CTT TAC.
The wild-type BOB.1/OBF.1 cDNA was cloned into the
expression vector pcDNA3. The cloning of the Oct2 and
PU.1 expression vectors has been described (50,51). For
in vitro translation of BOB.1/OBF.1 the pMT/PKA-Bob
expression vector was used (15).
Western blots
Proteins were prepared using lysis buffer containing 20 mM
Tris pH 7.5, 1 mM EDTA, 100 mM NaCl, 1% Triton X-100,
0.5% sodiumdeoxycholat and 0.1% SDS. Proteins were
resolved on a 12.5% SDS–PAGE and transferred to PVDF
membrane (Millipore). For immunodetection of Btk a
polyclonal anti-Btk antibody was used (BD). For detection
of Rel-A a Rel-A-speciﬁc polyclonal antibody (Santa Cruz
Biotechnology) was purchased. Proteins were visualized
using anti-mouse or anti-rabbit horseradish peroxidase
conjugated antibodies, respectively (Pierce) and the ECL
detection system (Amersham).
1808 Nucleic Acids Research, 2006, Vol. 34, No. 6Northern blots
Total RNA was prepared using the Trizol -reagent (Life
Technologies, Inc.) according to the protocol of the manufac-
turer. Afterseparation ofRNAsona1%formaldehydeagarose
gel, northern blot analyses were performed as described in
Ref. (52)
Electrophoretic mobility shift assay
Preparation of whole cell extracts for electrophoretic mobility
shift assay (EMSA) and the protocol of the EMSA procedure
have been described earlier (53,54). For EMSA, the following
oligonucleotides were annealed and subsequently labeled
using P
32 adCTP in a ﬁll-in reaction: mBtkprom 50-gcgg
AGA GGT CCC AGG CAA ATG TCG GGG GG, mBtk
prom 30-gcgg CCC CCC GAC ATT TGC CTG GGA CCT
CT; hBtkprom 50 gcgg AGA GGT CCC AAG CAA ATG
AAG GGC GG, hBtkprom 30-ggcg CCG CCC TTC ATT
TGC TTG GGA CCT CT; mBtkprom-Mut 50-gcgg AGA
GGT CCC AGT ACA ATG TCG GGG GG, mBtkprom-Mut
30-gcgg CCC CCC GAC ATT GTA CTG GGA CCT CT;
hBtkprom-Mut 50-gcgg AGA GGT CCC AGT ACA ATG
AAG GGC GG, hBtkprom-Mut 30-ggcg CCG CCC TTC
ATT GTA CTG GGA CCT CT; Oct consensus 50-gcgg
ACC TGG GTA ATT TGC ATT TCT AAA AT, Oct con-
sensus 30-gcgg ATT TTA GAA ATG CAA ATT ACC CAG
GT. For competition experiments, the unlabeled annealed
oligonucleotides were used. The indicated amount of oligo-
nucleotides was added to the EMSA reaction mixture. For
supershift experiments an anti-Oct1-antibody (serum), anti-
Oct2-antibody (C-20; Santa Cruz Biotechnology; no.
sc-233) or anti-BOB.1/OBF.1-antibody (serum) were used.
Modiﬁed EMSA conditions for the detection of speciﬁc
Oct/BOB.1/OBF.1 complexes were previously described
(55). In these experiments 2 mg HeLa-extracts and 2.5 ml
in vitro translated BOB.1/OBF.1 protein or the same amount
of unprogrammed TNT-lysates (Promega) were added where
indicated.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) Assay kit (Biomol
GmbH, Hamburg, Germany, #17-295) was used according to
the manufacturers instructions with minor modiﬁcations
described elsewhere (56). The samples were ampliﬁed using
Taq DNA polymerase (Amersham Pharmacia Biotech) using
the following primers: mBtkprom-ChIP 50-GGT TAT GAC
CTG TTG TTT GTT CAG C, mBtkprom-ChIP 30-CAC CCT
TTC GCA GCC ACT C. The primers for the analyses of the
H2B or Pax5 promoters are described in Ref. (56).
RESULTS
Identification of a non-perfect octamer sequences in
the human and murine Btk promoters
In search for BOB.1/OBF.1 target genes we analyzed the
promoter regions of genes implicated in B cell development
andfunctionforthepresenceoftheoctamermotif.Analyses of
the human and murine Btk promoters revealed a conserved
non-perfect octamer motif within the ﬁrst 200 bp upstream of
the start site of transcription (Figure 1). Both octamer motifs
differ from the consensus sequence ATGCAAAT at the
second position. The human Btk promoter motif bears a
T!A transversion, whereas the murine variant shows a
T!G transversion. Since it was shown that a mutation in
this position of the octamer motif interferes with Oct binding
(9) we wondered whether these sites might nevertheless play
a role for Btk promoter activity.
Figure 1. Comparative analysis of the human and murine Btk promoters. Nucleotide sequences of the human (+33 to  232 bp) and murine (+33 to  243 bp) Btk
promotersarepresented.Thepositionsoftheoctamermotif,theGT-,GC-andPu-boxesaswellastheinitiatorsiteandthestartsiteoftranscription(+1)areindicated.
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with labeled probes bearing either the consensus octamer
motif or the putative octamer binding sites identiﬁed in the
murine or human Btk promoters (Figure 2A and B). Although
complex formation was much weaker in the case of the Btk
promoter sites compared with the consensus octamer motif,
similar complexes could be detected upon extended exposure.
When the octamer motifs in the murine and human Btk
promoters were further mutated and then used as probes, no
speciﬁc binding could be detected (Figure 2C). Furthermore,
complex formation could be efﬁciently inhibited by competi-
tion with unlabeled oligonucleotides bearing the wild-type
murine or human Btk promoter octamer motifs. In contrast,
mutated octamer motifs failed to compete for Oct1 and Oct2
binding (Figure 2A and B). Competition was much more
efﬁcient when a consensus octamer motif was used
(Figure 2A and B). In supershift experiments we could dem-
onstrate that the shifted complexes contain Oct1 and Oct2
proteins(Figure 2D).Oct2-speciﬁc antibodies revealedseveral
supershifted complexes consistent with the existence of sev-
eral Oct2 isoforms (57). Together these ﬁndings indicate that
the identiﬁed octamer motifswithinthe murine andhumanBtk
promoters serve as binding sites for Oct1 and Oct2, although
showing reduced afﬁnities for Oct1 and Oct2 compared with a
consensus site.
Next we asked, whether BOB.1/OBF.1 is able to form
ternary complexes together with Oct1 and Oct2 on the murine
and human Btk promoters. It is extremely difﬁcult to obtain
ternary complexes even on consensus octamer motives by
EMSA with endogenous proteins in B cell extracts (55,58).
Therefore, we used an in vitro complementation system. HeLa
nuclear extracts were complemented with in vitro translated
BOB.1/OBF.1 and incubated with either the labeled the
consensus octamer motif or the motifs found in the human
or murine Btk promoters (Figure 3). Indeed, ternary complex
formation could be detected at these non-conserved octamer
sequences (Figure 3B and C, lane 3). Supershift experiments
revealed that these complexes were composed of Oct1 and
BOB.1/OBF.1 (Figure 3, lanes 4 and 5). BOB.1/OBF.1-
speciﬁc antibodies prevented ternary complex formation.
However, an Oct1 binding was still possible under these
conditions using the consensus octamer site as labeled
probe (compare lanes 2, 4 and 8 in Figure 3A). In contrast,
only very weak Oct1 binding could be detected with the non-
consensus Btk-octamer motifs (lanes 2, 4 and 8 in Figures 3B
and C). Moreover, the addition of anti-Oct1 antibodies leads to
a clear Oct1 supershift when the consensus octamer site was
used as probe (Figure 3A, lane 5). In contrast, no clear Oct1
supershift could be detected with the Btk octamer sites
(Figures 3B and C, lane 5). However, the ternary complex
formation was prevented, indicating that this complex is com-
posed of BOB.1/OBF.1 and Oct1. The addition of an anti-Oct2
antibody did not interfere with complex formation (Figure 3,
lane 6), since HeLa cells do not express Oct2. These data
indicate that in case of the non-consensus octamer sites
BOB.1/OBF.1 supports the binding of Oct1.
Figure2.OctamerfactorsOct1andOct2bindtothenon-consensusoctamersiteofthemurineandhumanBtkpromoters.(AandB)EMSAwithnuclearextractsfrom
the B cell lineBJAB and labeledprobespresenting either a consensusoctamersite(Oct cons)or the non-conserved octamersiteidentifiedin the human and murine
Btk promoters (murBtkprom, humBtkprom). Competitor binding sites with the wild-type (murBtkprom, humBtkprom) or mutated octamer mortif from the Btk
promoter[mBtkpromMut,humBtkpromMut;theoctamermotifsA(A/G)GCAAATweremutatedtoAgtacAAT]orwiththeconsensusoctamer(Octcons)sitewere
added in different molar excess (10·,3 0 ·, 100·). (C) The mutated sites were also unable to bind Oct1 or Oct2 proteins when tested as labeled probes. (D) EMSA
supershiftwiththeindicatedprobesandantibodiesspecificforOct1andOct2.EMSAexperimentsusingthenon-conservedoctamersiteidentifiedinthehumanand
murine Btk promoters (murBtkprom, humBtkprom) were exposed three-times longer than experiments where the wild-type octamer was used.
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promoter in vivo, ChIP experiments were performed using
primary B cells isolated from spleens of wild-type mice.
Oct1, Oct2 and BOB.1/OBF.1 are all bound to the murine
Btk promoter in B cells in vivo albeit with reduced afﬁnity
in comparison to the H2B promoter (Figure 4). To control for
the speciﬁcityofthe ChIP experiments,antibodies recognizing
unrelated proteins (PLCg1 and Lyn) were used for precipita-
tion. No signals were observed in these controls (Figure 4). In
addition, no binding of any of these proteins to the murine
Pax5 promoter that does not contain an octamer motif could be
observed.
Oct proteins transactivate together with BOB.1/OBF.1
the Btk promoter and act in synergy with PU.1
Since we observed binding of BOB.1/OBF.1 together with Oct
to the Btk promoter, we asked whether this binding results in
the activation of Btk promoter activity. Therefore, the murine
Btk promoter was cloned in front of a luciferase reporter gene
and transfected into NIH/3T3 cells along with Oct2,
BOB.1/OBF1 or with combinations of these expression
vectors. Consistent with our binding studies, we observed
that BOB.1/OBF.1 together with Oct2 was able to activate
the murine Btk promoter  150-fold in a dose-dependent man-
ner (Figure 5A, B and data not shown). Notably, Oct2 together
with BOB.1/OBF.1 was a potent inducer of Btk promoter
activity, whereas Oct1 had no effect at all (data not shown).
Since the transcription factor PU.1 was shown to be important
for the Btk promoter activity and the PU.1 sites are conserved
between the human and murine Btk promoters (Figure 1), we
wondered whether Oct2 and BOB.1/OBF.1 can enhance
PU.1-mediated transactivation of the Btk promoter. Transfec-
tion experiments using NIH/3T3 cells revealed that BOB.1/
OBF.1 together with PU.1 only marginally enhanced
PU.1-mediated Btk promoter activity. In contrast,
co-transfection of Oct2 together with PU.1 stimulated
PU.1-mediated Btk promoter activity signiﬁcantly (from 6-
to 75-fold). Moreover, co-transfection of PU.1 together with
Oct2and BOB.1/OBF.1led toaneven stronger andsynergistic
activation (325-fold) of the murine Btk promoter (Figure 5C).
In conclusion these ﬁndings indicate that the transcriptional
coactivator BOB.1/OBF.1 regulates the Btk promoter activity
in B cells in vitro as well as in vivo, in concert with Oct and
PU.1 proteins.
Expression of Btk is down-regulated in
BOB.1/OBF.1-deficient B cells
To further analyze the in vivo relevance of the Btk promoter
octamer motif we mutated the octamer sequence from AGG-
CAAAT to AGtacAAT. This mutation prevented binding of
Oct transcription factors (Figure 2C). When this mutated con-
struct was transfected into the murine B cell line S194 the
activity was reduced to 60% compared with the wild-type Btk
promoter (Figure 6A). This demonstrates that the octamer
motif signiﬁcantly contributes to overall promoter activity
in addition to the PU.1 and Sp1/Sp3 binding sites.
A prediction based on this result would be that Btk expres-
sion should be attenuated in B cells lacking BOB.1/OBF.1
expression. We therefore examined IL-7-dependent and
stroma cell-dependent pre B cell lines established from the
bone marrow of wild type and BOB.1/OBF.1
 /  mice for
expression of Btk (Figure 6B). Indeed, Btk protein expression
is reduced in BOB.1/OBF.1
 /  preB cells. The requirement of
BOB.1/OBF.1 for Btk expression in pre-B cell lines was fur-
ther analysed in IL-7-dependent cell lines expressing a con-
ditional BOB.1/OBF.1 transgene on a BOB.1/OBF.1
 / 
mutant background. To achieve conditional expression of
BOB.1.OBF.1 the tet-off system was used (27,56,59). In the
absence of Doxycyclin (Dox) the co-activator BOB.1/OBF.1
is expressed, whereas in the presence of Dox its expression is
repressed. RNA was prepared from either untreated or Dox
treated pre-B cells and analysed in northern blot experiments.
When BOB.1/OBF.1 expression was shut-off by doxycyclin
Figure 3. Ternarycomplexformationon Btkpromoteroctamermotifs.EMSA
experiments with HeLa nuclear extracts were performed using labeled probes
bearing either a consensus octamer motif (cons Oct site) or the octamer
sequences identified within the murine or human Btk promoter (Oct-hum
Btk prom, Oct-mur Btk prom). Unprogrammed reticulocyte lysate or in vitro
translated BOB.1/OBF.1 protein were included. Complexes were analyzed by
adding specific antibodies for Oct1, Oct2 or BOB.1/OBF.1 as indicated.
Figure 4. ChIP assay. BOB.1/OBF.1 binds together with Oct1 and Oct2 to the
murine Btk promoter. The chromatin of primary wild-type B cells was
cross-linked, sheared and immunoprecipitated with the indicated antibodies.
Immunoprecipitated DNA was purified and used as template in PCR with
primers specific for the murine Btk promoter ( 280 to  10), or for the
H2B and Pax5 promoters as internal controls. Chromatin immunoprecipitated
with anti-PLCg1 and anti-Lyn antibodies was included as negative controls.
Amplified products were detected on ethidium bromide stained agarose gels.
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the clear dependence of Btk expression in pre-B cells on
BOB.1/OBF.1 (Figure 6C). To investigate, whether the down-
regulationofBtkexpression intheabsenceofBOB.1/OBF.1 is
also seen in mature B220
+ cells, these cells were sorted by
FACS from spleens of wild type and BOB.1/OBF.1
 /  mice
and analyzed by protein immunoblot. Again, Btk expression
was strongly reduced in B220
+ BOB.1/OBF.1
 /  cells in
comparison with wild-type cells (Figure 6D). Furthermore,
in northern blot analyses of RNA prepared from splenocytes
of wild type or BOB.1/OBF.1
 /  mice a reduced Btk–mRNA
expression was detected when BOB.1/OBF.1 is not expressed
(Figure 6E). Together, these experiments clearly indicate the
physiological importance of BOB.1/OBF.1 for the B-cell-
speciﬁc expression of Btk.
DISCUSSION
The regulation of B cell type-speciﬁc gene expression plays an
essential role for B cell generation, maturation, development
and function. A large number of transcription factors have
been shown to be involved in the regulation of B cell fate
(60). One of those factors is the transcriptional coactivator
BOB.1/OBF.1, which enhances the transcriptional activity
of the Oct1 and Oct2 transcription factors. To get more
insights into the physiological role of BOB.1/OBF.1 the
transcriptional network controlled by BOB.1/OBF.1 needs
to be elucidated.
Here we show that BOB.1/OBF.1 regulates Btk gene
expression. Although the Btk promoter had been analyzed
quite extensively for binding of transcription factors
Figure 5. Analysis of the dependence of the murine Btk promoter activity on Oct and BOB.1/OBF.1 proteins in transient transfection experiments using NIH/3T3
fibroblasts. Activity of the murine Btk promoter without co-transfection was set to one. The fold induction upon co-transfection of Oct2, BOB.1/OBF.1 or PU.1 or
combinationsoftheseexpressionvectorswasdetermined.TheexperimentswererepeatedfivetimesandmeanvaluesaswellasSDweredetermined.(A)Themurine
BtkpromoterisinducedwhenOct2andBOB.1/OBF.1arecoexpressed.(B)TheactivationofthemurineBtkpromoterbyOct2andBOB.1/OBF.1isdose-dependent.
(C) Synergistic activation of the murine Btk promoter by Oct2, BOB.1/OBF.1, and PU.1.
1812 Nucleic Acids Research, 2006, Vol. 34, No. 6(44–49), the presence of a functional octamer site within the
ﬁrst 200 bp upstream of the start site of transcription had not
been reported. Although footprint experiments identiﬁed a
protected region in the human Btk promoter region extending
from  130 to  152 bp (the human Btk promoter octamer
motif is located at  145 to  152 bp; see Figure 1), this
area was only analyzed for the binding of Sp1/3 factors to
the GC rich box (48). In addition, the DNA probe used in gel
shift experiments to detect Sp1/3 binding did not encompass
the octamer motif. Therefore, protein–DNA complexes
reﬂecting Oct binding to the Btk promoter could not be
observed in these experiments. Furthermore, in search for
factors involved in cell-type-speciﬁc Btk expression, those
protein complexes observed in gel shift experiments were
excluded from detailed analyses that were found to bind to
theBtkpromoteralsoincellswere Btkisnotexpressedsuchas
T cells and ﬁbroblasts (46). However, Oct proteins are not
exclusively expressed in B cells and Oct1 is also found in
T cells and ﬁbroblasts. We could show that Oct1 as well
Oct2 are able to bind to the murine as well to the human
Btk promoter, albeit this binding activity was much weaker
than that observed using a consensus octamer site. In addition,
ternary complexes composed of Oct1 and BOB.1/OBF.1 could
be detected on the murine and human Btk Oct sites in a recon-
stituted system. This clearly demonstrates that Oct proteins
together with BOB.1/OBF.1 are able to bind to the non-perfect
Oct motifs found in the Btk promoter in vitro. Interestingly,
whereas in the absence of BOB.1/OBF.1 only a weak binding
of Oct factors was observed, the ternary complex formation
was found similar to that formed on the consensus octamer
motif.
Similar results were observed when the Oct-dependent and
BOB.1/OBF.1-dependent osteopontin promoter had been ana-
lyzed (61,62). This promoter contains a PORE (Palindromic
Oct factor Recognition Element; ATTTG(N5)CAAAT) that
enables Oct factors to assemble homo- or hetero-dimers at this
site in vitro. The PORE-mediated Oct dimerization was sug-
gested to be an essential prerequisite for binding of BOB.1/
OBF.1 to such an octamer site (63). These studies also demon-
strated that the transversion T!G at the second position of the
consensus octamer site (identiﬁed in the murine Btk promoter)
impairs Oct binding. However, luciferase reporter assays
revealed that the T!G transversion results in increased pro-
moter activity in comparison to the wild-type PORE promoter
(62). In line with this observation it was shown that the pres-
ence of BOB.1/OBF.1 enables Oct factors to bind to this
unfavorable non-consensus octamer motifs (62). Although
the octamer motifs identiﬁed in Btk promoter do not represent
classical PORE motifs, we show here that Oct proteins and
BOB.1/OBF.1 bind to this site in vitro. Thus the presence of
BOB.1/OBF.1 facilitates binding of Oct proteins to at least a
subset of non-consensus octamer motifs.
Figure 6. ThetranscriptionalcoactivatorBOB.1/OBF.1iscriticalforBtkexpressioninvivo.(A)Mutationswithintheoctamermotifofthemurinebtkpromoterlead
toareductionofpromoteractivity.ThemurineS194Bcelllinewastransfectedwitheitherthewildtype(murBtkpr)orthemutantBtkpromoter(mBtkprMut).The
activity of the wild-type promoter was set to 100%. The activity of the mutant Btk promoter was determined relative to the wild-type promoter activity. The
experimentswererepeatedfivetimesandmeanvaluesaswellasSDweredetermined.(B)ProteinextractsfrompreBcelllinesestablishedfromthebonemarrowof
wildtypeorBOB.1/OBF.1
 / micewereanalyzedforBtkexpressionbywesternblot.(C)RNApreparedfrombonemarrowderivedpreBcelllines,establishedfrom
mice expressing a conditional BOB.1/OBF.1 transgene on a BOB.1/OBF.1-mutant background, was analyzed for Btk mRNA expression by northern blot. In the
absence of Doxycyclin (Dox) the co-activator BOB.1/OBF.1 is expressed, whereas in the presence of Dox its expression is repressed. (D) Protein extracts were
preparedfrom sorted B220
+ splenocytesfrom either wild typeor BOB.1/OBF.1
 /  miceand analyzed for Btk expression. (E) RNA waspreparedfrom splenocytes
fromwildtypeorBOB.1/OBF.1
 / miceandtheBtk–mRNAexpressionwasanalyzedbynorthernblot.RelA(p65)orGAPDHwereusedasloadingcontrols.WB¼
western blot; NB ¼ northern blot.
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also occurs in vivo. Furthermore, Oct and BOB.1/OBF.1
proteins act in synergy with PU.1—a previously identiﬁed
factor important for Btk promoter regulation (46,48,49)—to
induce Btk promoter activity. Since the PU.1 binding site
identiﬁed in the human Btk promoter is conserved and present
in the murine Btk promoter (Figure 1) we suggest that the
mechanism of Btk gene regulation by Oct/BOB.1/OBF.1 and
PU.1 is conserved between mouse and humans. The import-
ance of PU.1 for Btk gene regulation is underlined by the fact
that the absence of PU.1 leads to a two- to 3-fold reduction of
Btk expression (48). In contrast, the deﬁciency of Sp1 that also
stimulates Btk promoter activity together with PU.1 (49) had
no inﬂuence on Btk expression (49). Here we showed that
BOB.1/OBF.1-deﬁciency results in a severe reduction of
Btk expression in immature bone marrow derived pre-B
cells as well as in peripheral B220
+ splenocytes. These data
indicate the physiological importance of Oct/BOB.1/OBF.1
together with PU.1 in B cell-speciﬁc Btk gene regulation at
early and late stages of B cell development.
If Btk is a direct target of BOB.1/OBF.1 the phenotype of
mice deﬁcient in either BOB.1/OBF.1 or Btk should be
related. Indeed, both knock-out mice share similar character-
istics, like defects in B cell development in bone marrow and
spleen, resulting in a 2- to 4-fold reduction of peripheral B cell
number and defects in B cell receptor signaling. However,
both knock-out mice have also unique features: whereas the
marginal zone B cell compartment is almost missing in
BOB.1/OBF.1
 /  mice (27) this B cell subset was found
normal in Xid mice. In contrast, the B-1 population is depleted
in Xid mice (33,34,64) and normal in BOB.1/OBF.1
 /  mice.
In addition, mice mutant for both proteins show a more severe
defect than each mouse itself. This phenotype resembles that
of severe agammaglobulinemia in human XLA (31,39).
Therefore, Btk and BOB.1/OBF.1 seem to be involved in
overlapping as well as distinct signaling pathways.
Taken together, the analyses of the murine and human Btk
promoter revealed the presence of a functional octamer motif.
The transcription factors Oct1/2 as well as the coactivator
BOB.1/OBF.1 bind to these sites in vitro and in vivo. The
physiological relevance of the octamer was shown in
BOB.1/OBF.1
 /  B cells were the expression of Btk is
strongly reduced. The ﬁnding that the presence of BOB.1/
OBF.1 facilitates the binding of Oct factors to the non-
consensus octamer sequence identiﬁed in the human and mur-
ine Btk promoters could reﬂect a mechanism of ﬁne-tuned
regulation of promoter activity depending on Oct and
BOB.1/OBF.1.
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